Company profile: LB Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of development-stage CNS therapeutics focused on LB-102 (n-Methyl amisulpride), a modified amisulpride for schizophrenia, and clinical trials assessing its safety, efficacy, and pharmacokinetics. Also develops improved versions of CNS treatments widely used overseas but not FDA approved for commercialization in the United States.
Products and services
- Clinical Trials for LB-102: Architects clinical-stage studies evaluating safety, efficacy, and pharmacokinetics of LB-102 in schizophrenia, generating evidence to support U.S. development and potential approval
- Development of CNS Disorder Treatments: Engineers a research-focused organization to create improved versions of successful overseas CNS products lacking U.S. FDA approval, generating novel intellectual property for domestic commercialization
- LB-102: Builds a novel n-Methyl amisulpride antipsychotic tailored for U.S. schizophrenia treatment, modified to potentially improve efficacy and safety compared with amisulpride
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LB Pharmaceuticals
Aderis Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical products for the diagnosis and treatment of cardio-renal and cardiovascular diseases, including adenosine agonists and antagonists; focused on discovery, development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aderis Pharmaceuticals company profile →
Nfocus Neuro
HQ: United States
Website
- Description: Provider of endovascular neurosurgery solutions, designing, developing, and marketing systems to treat intracranial aneurysms and neurovascular disease, including brain aneurysms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nfocus Neuro company profile →
Tryp Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage psilocybin-based therapeutics, developing an IV infusion of psilocin and synthetic oral psilocybin to address neuropsychiatric disorders, orphan diseases, and conditions with no effective first-line treatments. Offerings include TRP-8803, a proprietary IV psilocin formulation, TRP-8802 in early-stage trials, and Phase 2a studies in fibromyalgia, binge eating disorder, and irritable bowel syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tryp Therapeutics company profile →
Phagenesis
HQ: United Kingdom
Website
- Description: Provider of neurostimulation solutions for dysphagia treatment, developing the Phagenyx System, which delivers Pharyngeal Electrical Stimulation to restore neurological control of swallowing. The system tailors stimulation to patient sensory capacity and uses a dual-function catheter for feeding and electrical therapy, harnessing neuroplasticity to improve safe swallowing in patients, including those post-stroke or with neuro-deficit diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phagenesis company profile →
Spiegelberg
HQ: Germany
Website
- Description: Provider of catheters and probes for neurosurgical use in the brain, as well as antimicrobial products to prevent hospital-acquired infections; began operation in 1986 and is headquartered in Hamburg, Germany.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spiegelberg company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LB Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LB Pharmaceuticals
2.2 - Growth funds investing in similar companies to LB Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LB Pharmaceuticals
4.2 - Public trading comparable groups for LB Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →